Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: A Collaborative Pediatric Branch, National Cancer Institute and Children's Cancer Group trial

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1538-1543

  Blaney, S M ^a   Seibel, N L ^a   O'Brien, M ^a   Reaman, G H ^a   Berg, S L ^a   Adamson, P C ^a   Poplack, D G ^a   Krailo, M D ^a   Mosher, R ^a   Balis, F M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG INFUSION; DRUG TOLERANCE; EWING SARCOMA; FEMALE; HEPATOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; NEPHROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RHABDOMYOSARCOMA; SOLID TUMOR;

EID: 0030895964     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1538     Document Type: Article

References (16)

1. Cortes J, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
2. Bissery MC, Guenard D, Gueritte VF, et al: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991
3. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34:992-998, 1991
4. Ringel I, Horwitz S: Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991
5. Hanauske AR, Degen D, Hilsenbeck SG, et al: Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3:121-124, 1992
6. ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527-532, 1994
7. Eisenhauer E, Trudeau M: An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Cancer 31A:1-3, 1995 (Suppl 4)
8. Cerny T, Kaplan S, Pavlidis N. et al: Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 70:384-387, 1994
9. Francis P, Rigas J, Kris M, et al: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237, 1994
10. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
11. Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 30A:1058-1060, 1994
12. Sulkes A, Smyth J, Sessa C, et al: Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. EORTC Early Clinical Trials Group [see comments]. Br J Cancer 70:380-383, 1994
13. Catimel G, Verweij J, Mattijssen V, et al: Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5:533-537, 1994
14. Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308, 1994
15. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD. Division of Cancer Treatment, National Cancer Institute, 1988
16. Hurwitz C, Relling M, Weitman S, et al: Phase I trial of paclitaxel in children with refractory solid tumors: A Pediatric Oncology Group study. J Clin Oncol 11:2324-2329, 1993